The advocates for, and the critics of, the drug industry are both often guilty of misrepresenting the industry's economics. Some misrepresentations follow from technical ignorance. Some appear willful, to serve a policy objective. Jack explains some of the more egregious kinds of mis-analysis. It will include a discussion of drug industry profits; whether or not the industry is "over-earning" versus other industrial sectors and versus the wider value of pharmaceutical innovation.